Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTM2 | P28161 | 6/20 | 0.53 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.45 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 5/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762713 | 0.89 | GSTM2 (0.57) | GSTM2MYCHRH3S1PR1S1PR3 | |
| SCHEMBL6759054 | 0.88 | GSTM2 (0.56) | GSTM2MYCHRH3S1PR1S1PR3 | |
| SCHEMBL17240248 | 0.83 | S1PR1 (0.56) | GSTM2HRH3S1PR1S1PR3S1PR4 | |
| SCHEMBL12272715 | 0.83 | S1PR1 (0.56) | GSTM2HRH3S1PR1S1PR3S1PR4 | |
| SCHEMBL6759014 | 0.82 | GSTM2 (0.57) | GSTM2MYCHRH3S1PR1S1PR3 | |
| SCHEMBL6510371 | 0.81 | S1PR1 (0.48) | GSTM2HRH3S1PR1S1PR3S1PR4 | |
| SCHEMBL6704299 | 0.81 | S1PR1 (0.48) | GSTM2HRH3S1PR1S1PR3S1PR4 | |
| SCHEMBL6762830 | 0.80 | GSTM2 (0.64) | GSTM2MYCHRH3S1PR1S1PR3 | |
| SCHEMBL1436399 | 0.80 | SMN1; SMN2 (0.61) | GSTM2S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1535067 | 0.80 | SMN1; SMN2 (0.61) | GSTM2S1PR1S1PR3S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6783949-B1 | REACTING FLUORESCENTLY LABELED FATTY ACID WITH 2,3-EPOXYPROPANOL TO FORM MONOGLYCERIDE WHICH IS SUBJECTED TO ULTRASONIC TREATMENT WITH PHOSPHOLIPIDS; DRUG SCREENING; FOR DETECTING METABOLIC DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-31 | — | — | US | disclosed |